Navigation Links
United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Date:2/15/2011

,19164,139Total selling, general and administrative expense

$

74,998$

56,577$

199,600$

176,338Sales and marketing.  The increase in sales and marketing expenses of $2.3 million for the quarter ended December 31, 2010 compared to the same quarter in 2009, is predominately due to an increase in payroll and training-related expenses as a result of our headcount expansion of approximately 50 sales and marketing personnel during the quarter ended December 31, 2010.

Share-based compensation.  For the quarter ended December 31, 2010, share-based compensation increased by $16.7 million over the same period in 2009 as a result of a $10.9 million increase in share-based compensation recognized for our STAP due to the same factors noted above and an $8.8 million increase related to a year-end stock option award to our Chief Executive Officer primarily as a result of the appreciation in the price of our common stock over the year.

Income Tax Benefit. We recognized income tax benefits of $5.0 million and $1.4 million for the quarter ended December 31, 2010 and 2009, respectively. The $3.6 million increase in income tax benefits recognized during the quarter ended December 31, 2010 corresponded to increases in the domestic manufacturing deduction and business tax credits generated from our orphan drug-related research and development activities.

Earnings Before Non-Cash ChargesEarnings before non-cash charges is defined as net income, adjusted for the following non-cash charges, as applicable: (1) interest; (2) income taxes; (3) license fees; (4) depreciation and amortization; (5) impairment charges; and (6) share-based compensation (stock option and share tracking award expense).

A reconciliation of net income (loss) to earnings before non-cash charges is presented below (in thousands, except per share data):Year Ended D
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
5. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
6. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
7. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
8. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
9. United Therapeutics Reports Third Quarter 2008 Financial Results
10. Lilly Contributes $11.1 Million to United Way Annual Campaign
11. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  In recognition of World ... with hemophilia advocacy groups to illuminate more than 15 prominent ... including Boston,s Zakim Bridge and Prudential ... New Orleans, Mercedes-Benz Superdome and Denver,s ... during the evening of April 17, and coincide with hemophilia ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... The state of the microRNA market and the molecule,s, ... diagnostics, ... - TIME: 3 pm EDT, ... Christi Bird, Senior Research Analyst, Healthcare, ...
... Ear Diseases to Guide Novel Treatments to ClinicSAN ... its scientific advisory board comprised of physicians and ... the ear. The advisory board includes three of ... Harris, M.D., Ph.D.; and Allen Ryan, Ph.D. Joining ...
... leading campus recruitment company, has announced the official ... new website is designed for students, recent graduates, ... the biotechnology, pharmaceutical, and life sciences industries. With ... more people are considering a career in these ...
Cached Biology Technology:Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics 2Otonomy Introduces Scientific Advisory Board 2Otonomy Introduces Scientific Advisory Board 3Otonomy Introduces Scientific Advisory Board 4Otonomy Introduces Scientific Advisory Board 5Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio 2Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio 3
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... In the first study of its kind, researchers ... have found that low socioeconomic status (SES) and maternal ... of attention deficit hyperactivity disorder (ADHD) in six year ... of the Archives of Pediatrics and Adolescent Medicine ...
... Northeast Public Radio and the Cary Institute of Ecosystem Studies ... look at our changing environment. The collaboration was formed to ... raising awareness about the science that underpins environmental issues. ... 11:10 AM and 4:04 PM on WAMC. With the ...
... in German . , Many animals produce ... kin or mates are present than other audience members. So ... the other group members, knowledge state into account. Researchers from ... and the University of St. Andrews, Great Britain, set up ...
Cached Biology News:Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2Cary Institute and WAMC debut new environment radio show 2I know something you don't know -- and I will tell you! 2
... of Wyatt Technology's family of light scattering ... high temperature chromatograph and enables you to ... polymers. The HTmD is easily installed in ... or Alliance 2000 device and enables you ...
...
... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. ... GAS. A cell-permeable sulfanamido-benzbromarone compound that ... non-competitive allosteric inhibitor of PTP1B (IC ... 8 μM for PTP1B 403 ...
... White walled plates enhance luminescent ... and fluorescence,• Not treated (or medium ... nature and binds biomolecules through passive ... immobilization of large molecules, such as ...
Biology Products: